Taking legal advice on EU's medicine ban: Commerce Secretary

Press Trust of India New Delhi
Last Updated : Aug 24 2015 | 12:40 AM IST
India is seeking “legal advice” to deal with the recent ban imposed by the European Union (EU) on 700 medicines clinically tested by GVK Biosciences, a top official said.

“We are certainly exploring what are the options for India. We are taking legal advice... We will take a call on this to move forward,” Commerce Secretary Rita Teaotia told PTI.

The largest EU-wide suspension of sales and distribution of generic drugs ordered by the European Commission, has already come into effect and will be applicable to all 28 member nations, according to Germany’s drug regulator, the Federal Institute for Medicines and Medical Products.

Peeved at the move, India has already deferred talks with the EU on the proposed free trade agreement. India-EU trade talks, launched in June 2007, remain stuck as both sides are not satisfied with each other’s offers.

Teaotia added India also has the option to use a global framework to resolve the issue. The EU has banned the marketing of around 700 generic medicines for alleged manipulation of clinical trials conducted by the Hyderabad-based GVK Biosciences.

Industry body Pharmexcil pegs India’s business loss from the EU ban at around $1.2 billion.

The pharmaceutical sector, which contributes over $20 billion in India, is facing a lot of regulatory issues in several developed countries, including the US.

In 2014-15, India’s pharmaceuticals exports grew 2.63 per cent to $15.34 billion.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 24 2015 | 12:06 AM IST

Next Story